Ladenburg Thalmann Downgrades Zosano Pharma (ZSAN) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Ladenburg Thalmann Downgrades Zosano Pharma (ZSAN) to Neutral

Zosano Pharma Reports Second Quarter 2016 Financial Results

August 10, 2016 4:15 PM EDT

FREMONT, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the second quarter ended June 30, 2016.

With the recent announcement of the first subject treated in our M207 pivotal efficacy trial for acute migraine, we remain on track to report data in Q1 2017, said Dr. Konstantinos Alataris, Zosanos President and Chief Executive Officer.  I look forward to providing additional updates as the trial progresses.  As of August 8, 2016, 196 subjects were... More